Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Gene Therapy00:59

Gene Therapy

25.1K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Chemical priming potentiates mesothelin-targeting chimeric antigen receptor-engineered NK-92 antitumor activity by improving tumor trafficking and cytotoxic killing dynamics.

Frontiers in immunology·2026
Same author

Lewis antigen and antibody testing as practical first-line approaches for detecting CA19-9 non-producers.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2026
Same author

Overcoming resistance in CD44-overexpressing myeloma through combination therapy with ATRA, bortezomib, and NK cells.

Cancer immunology, immunotherapy : CII·2026
Same author

BaEV-pseudotyped lentiviral vectors enable stable CAR expression and cytotoxic function in NK cells.

PloS one·2026
Same author

Quantitative assessment of extravasation of IL-15-secreting MSLN-CAR-NK-92 cells using tumor transparency imaging.

Theranostics·2026
Same author

An automatic consult reply system for therapeutic plasma exchange using retrieval-augmented generation.

Vox sanguinis·2026

相关实验视频

Updated: May 23, 2025

Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells
08:42

Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells

Published on: January 15, 2018

11.0K

通过微流体基因传递推进异构NK细胞免疫疗法

Hyelee Kim1,2, Mujin Lee3, Bohwa Han3

  • 1Department of Bioengineering, Korea University, Seoul, 02841, Republic of Korea.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|March 7, 2025
PubMed
概括

一种新的微流体装置,Y-hydroporator,有效地设计了化学抗原受体 (CAR) -自然杀手 (NK) 细胞用于癌症免疫疗法. 这项技术增强NK细胞的细胞毒性,同时保持活力,为改进的全基性免疫疗法铺平了道路.

关键词:
卡恩克 (CAR-NK) 是一个国家.克里斯普尔是什么意思?克里斯普尔是什么意思?基于NK细胞的免疫疗法.全源细胞疗法全源细胞疗法基因传递 基因传递 基因传递微流体学 在微流体学方面

更多相关视频

Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System
08:29

Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System

Published on: October 4, 2024

591
A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro
10:36

A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro

Published on: January 9, 2018

7.1K

相关实验视频

Last Updated: May 23, 2025

Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells
08:42

Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells

Published on: January 15, 2018

11.0K
Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System
08:29

Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System

Published on: October 4, 2024

591
A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro
10:36

A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro

Published on: January 9, 2018

7.1K

科学领域:

  • 生物技术是生物技术.
  • 免疫治疗是一种免疫疗法.
  • 细胞工程 细胞工程

背景情况:

  • 化学抗原受体 (CAR) -T细胞疗法显示出希望,但面临着制造和安全方面的挑战.
  • 天然杀手 (NK) 细胞治疗提供了具有先天性细胞毒性和降低安全风险的替代方案.
  • 高效的基因工程和大规模生产异性NK细胞是关键的未满足需求.

研究的目的:

  • 开发一种新型的微流体平台,以有效地将基因传递给异性NK细胞.
  • 克服CAR-NK细胞免疫疗法的制造和工程障碍.
  • 为了证明平台在产生功能性工程NK细胞方面的能力.

主要方法:

  • 开发了Y-hydroporator,这是一种具有Y形通道的微流体装置,用于NK细胞的水力动力拉伸.
  • 使用Y-水分器将mRNA和CRISPR/Cas9核糖蛋白传递给人类NK细胞.
  • 在分娩后评估细胞活力,功能和转染效率.

主要成果:

  • 该Y-hydroporator实现了高的传递和转染效率 (≈2 × 106细胞min-1) 与高细胞活力 (>89%).
  • 成功生成了抗CD19的CAR-NK细胞和NKG2A淘汰NK细胞.
  • 工程NK细胞表现出对细胞的增强细胞毒性活性.

结论:

  • Y-hydroporator是一种高效且可行的平台,用于设计异性NK细胞.
  • 这项技术有可能推进NK细胞基础免疫疗法的开发和应用.
  • 该平台解决了用于癌症治疗的CAR-NK细胞制造的关键挑战.